Supplementary Information:

Lipid Aging Clocks as predictive and prognostic biomarker in cancer and inflammaging

Authors: Maximilian Unfried^{1,2**}, Amaury Cazenave-Gassiot^{2,3,4}, Evelyne Bischof^{5,6,7}, Michal Holcapek⁸, Morten Scheibye-Knudsen⁹, Markus R. Wenk^{2,3,4,10}, Jan Gruber^{1,11**}, Brian K. Kennedy^{1,2,12**}

1 Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

2 Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117608, Singapore

3 Singapore Lipidomics Incubator, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore

4 Precision Medicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

5 Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

6 Shanghai University of Medicine and Health Sciences, Shanghai, China

7 Sheba Longevity Center, Sheba Medical Center, Tel Aviv, Israel

8 Department of Analytical Chemistry, Faculty of Chemical Technology, University of Pardubice, , 53210 Pardubice, Czech Republic

9 Department of Cellular and Molecular Medicine, University of Copenhagen, Denmark

10 College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar

11 Science Divisions, Yale-NUS College, Singapore 138527, Singapore

12 Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117608, Singapore

** Corresponding Author



Sup. Figure 1: Uncentered results



Sup. Figure 2: Correlation between LAA and Overall and Progression free survival



Sup. Figure 3: Correlation between log2 CA19-9 and LAA



Sup. Figure 4: Lipid Species in the LipidClock and their Hazard Ratios.



Sup. Figure 5: Separation by the 7 lipids with the largest HR



Sup. Figure 6: Difference of lipid species between healthy and PDAC

Sup. Table 1: Metrics on validation Data

	Mean	Median	Mean Squared	R2-Score	
	Absolute Error	Absolute Error	Error		
Healthy	6.223	4.85	65.237	0.536	
PDAC	11.997	10.088	241.098	-1.216	
Pancreatits	7.266	6.432	84.160	0.453	

Sup. Table 2: Cox proportional Hazard model for individual models of LipidAge, LAA and CA 19-9 for Progression Free Survival

Covariate	Hazard	95% CI	SE	Z	p-value
	Ratio				
LipidAge	1.02	1.01-1.03	0.01	3.65	<0.005
Lipid Age	1.03	1.01-1.05	0.01	3.72	<0.005
Acceleration					
Binary Lipid	1.65	1.08-2.50	0.21	2.38	0.02
Age					
Acceleration					
Log2 CA	1.09	1.04-1.13	0.02	3.96	<0.005
19-9					
Binary CA	2.13	1.41-3.22	0.21	3.57	<0.005
19-9					

Sup. Table 3: Combined model of LAA and Log2 CA 19-9 for Progression Free Survival

Covariate	Hazard	95% CI	SE	Z	p-value
	Ratio				
Lipid Age	1.02	1.00-1.04	0.01	2.20	0.03
Acceleration					
Log2 CA	1.06	1.01-1.11	0.02	2.42	0.02
19-9					

Sup. Table 4: Combined model of binary LAA and binary CA 19-9 for Progression Free Survival

Covariate	Hazard	95% CI	SE	Z	p-value
	Ratio				
Binary Lipid	1.56	1.03-2.38	0.21	2.08	0.04
Age					
Acceleration					
Binary CA	2.06	1.36-3.12	0.21	3.39	<0.005
19-9					